報價延遲最少15分鐘:2025/04/29 15:01 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
76.39 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
6.97/2.72
|
|
企業價值
44.92B
|
| 資產負債 |
|
每股賬面淨值
17.07
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
5.44B
|
|
每股收益
9.93
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/29 15:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |